AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
17 oct. 2023 07h00 HE
|
AC Immune SA
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
05 oct. 2023 07h00 HE
|
AC Immune SA
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company...
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
05 sept. 2023 07h00 HE
|
AC Immune SA
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage...
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
04 août 2023 07h00 HE
|
AC Immune SA
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat...
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
28 juil. 2023 07h00 HE
|
AC Immune SA
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
AC Immune SA Appoints New Chief Medical Officer
26 juil. 2023 07h00 HE
|
AC Immune SA
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:...
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
03 juil. 2023 07h00 HE
|
AC Immune SA
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
27 juin 2023 07h00 HE
|
AC Immune SA
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites...
AC Immune Holds Annual General Meeting of Shareholders
23 juin 2023 16h30 HE
|
AC Immune SA
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ:...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
28 avr. 2023 07h00 HE
|
AC Immune SA
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease...